Literature DB >> 2012547

Clinical use of the 193-nm excimer laser in the treatment of corneal scars.

N A Sher1, R A Bowers, R W Zabel, J M Frantz, R A Eiferman, D C Brown, J J Rowsey, P Parker, V Chen, R L Lindstrom.   

Abstract

Phototherapeutic keratectomy using a 193-nm excimer laser was performed at four centers on 33 sighted patients with corneal opacity and/or irregular astigmatism. Pathologic conditions included anterior stromal and superficial scarring from postinfectious and posttraumatic causes, including inactive herpes simplex virus, anterior corneal dystrophies, recurrent erosions, granular dystrophy, and band keratopathy. Most patients received peribulbar anesthesia and underwent removal of the epithelium prior to laser ablation. A majority of patients had a reduction in the amount of corneal scarring and approximately half had improved visual acuity. No intraocular reaction or changes in endothelial counts were seen, and some patients avoided the need for penetrating keratoplasty. Reepithelialization usually occurred within 4 or 5 days and we noted no significant scarring secondary to use of the laser. It was difficult to eliminate preexisting irregular astigmatism despite the use of surface modulators, such as methylcellulose. A hyperopic shift secondary to corneal flattening was encountered in approximately 50% of the patients. A combination of myopic ablation, followed immediately by a secondary hyperopic steepening, may minimize this refractive change. The 193-nm excimer laser is an effective new tool in the treatment of selected patients with superficial corneal opacity from a variety of conditions.

Entities:  

Mesh:

Year:  1991        PMID: 2012547     DOI: 10.1001/archopht.1991.01080040059027

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

1.  Photorefractive keratectomy.

Authors:  P J McDonnell
Journal:  West J Med       Date:  1992-10

2.  Excimer laser photorefractive keratectomy in high myopia: a multicenter study.

Authors:  R L Lindstrom; N A Sher; M Barak; J DeMarchi; A Tucci; S Daya; D R Hardten; J M Frantz; R A Eifermn; P Parker
Journal:  Trans Am Ophthalmol Soc       Date:  1992

3.  Compensatory epithelial hyperplasia in human corneal disease.

Authors:  R C Eagle; E C Dillon; P R Laibson
Journal:  Trans Am Ophthalmol Soc       Date:  1992

4.  Hyperopic shift and the use of masking agents in excimer laser superficial keratectomy.

Authors:  C Liu
Journal:  Br J Ophthalmol       Date:  1992-01       Impact factor: 4.638

5.  Use of the 193-NM excimer laser for myopic photorefractive keratectomy in sighted eyes: a multicenter study.

Authors:  R L Lindstrom; N A Sher; V Chen; R A Bowers; J M Frantz; D C Brown; R Eiferman; S S Lane; P Parker; C Ostrov
Journal:  Trans Am Ophthalmol Soc       Date:  1991

6.  Direct chemical analysis of uv laser ablation products of organic polymers by using selective ion monitoring mode in gas chromatography/mass spectrometry.

Authors:  Y Choi; H Lee; S T Fountain; D M Lubman
Journal:  J Am Soc Mass Spectrom       Date:  1994-02       Impact factor: 3.109

7.  Effect of ablation profile on wound healing and visual performance 1 year after excimer laser photorefractive keratectomy.

Authors:  M C Corbett; S Verma; D P O'Brart; K M Oliver; G Heacock; J Marshall
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

8.  Therapeutic use of the 193-nm excimer laser in corneal pathologies.

Authors:  W Förster; U Atzler; I Ratkay; H Busse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-05       Impact factor: 3.117

9.  Vimentin and cytokeratin pattern in granular corneal dystrophy.

Authors:  G Wollensak; H Witschel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

10.  Excimer laser phototherapeutic keratectomy in eyes with anterior corneal dystrophies: preoperative and postoperative ultrasound biomicroscopic examination and short-term clinical outcomes with and without an antihyperopia treatment.

Authors:  Christopher J Rapuano
Journal:  Trans Am Ophthalmol Soc       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.